Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol.

Lemay A, Brideau NA, Forest JC, Dodin S, Maheux R

Clinical endocrinology1 Oct 1991Cited by 18 (Europe PMC)

PMID1836425DOI10.1111/j.1365-2265.1991.tb03541.xPepBankPUB-01836425

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In endometriosis patients after one month, oestradiol remained in the menopausal range with goserelin and the early follicular range with danazol.
In plain wordsIn endometriosis patients, estrogen remained in the menopausal range with goserelin and the early follicular range with danazol after one month.
Peptide
Goserelin
Outcome
Direction not reportedSerum oestradiol
Study
n = 33
Comparator
Danazol
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
After 1 month of therapy, serum oestradiol levels were maintained in the menopausal range with goserelin and in the early follicular phase range with danazol.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642501
02HumanRandomized controlled trialActivity measurement
In endometriosis patients, lipoprotein changes during goserelin favorably affected the cholesterol/HDL-C index, whereas danazol had opposite effects.
In plain wordsIn endometriosis patients, goserelin favorably affected the cholesterol/HDL cholesterol index, while danazol had opposite effects.
Peptide
Goserelin
Outcome
Direction not reportedAtherogenic index
Study
n = 33
Comparator
Danazol
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
The lipoprotein changes during goserelin had a favourable effect on the atherogenic index (cholesterol/HDL-C) and ApoA-1/ApoB ratio whereas those of danazol had opposite effects.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642508
03HumanRandomized controlled trialActivity measurement
In endometriosis patients, lipoprotein changes during goserelin favorably affected the ApoA-1/ApoB ratio, whereas danazol had opposite effects.
In plain wordsIn endometriosis patients, goserelin favorably affected the ApoA-1/ApoB ratio, while danazol had opposite effects.
Peptide
Goserelin
Outcome
Direction not reportedApoA-1/ApoB ratio
Study
n = 33
Comparator
Danazol
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
The lipoprotein changes during goserelin had a favourable effect on the atherogenic index (cholesterol/HDL-C) and ApoA-1/ApoB ratio whereas those of danazol had opposite effects.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642509
04HumanNon-randomized trialActivity measurement
In endometriosis patients, goserelin significantly increased HDL-C by 31.4%.
In plain wordsIn endometriosis patients, goserelin increased HDL cholesterol by 31.4%.
Peptide
Goserelin
Outcome
IncreaseHDL-C
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Measurements
HDL-C increase
31.4%
goserelin
Source sentences
Summary
Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642502
05HumanNon-randomized trialActivity measurement
In endometriosis patients, goserelin significantly increased HDL2-C by 24.6%.
In plain wordsIn endometriosis patients, goserelin increased HDL2 cholesterol by 24.6%.
Peptide
Goserelin
Outcome
IncreaseHDL2-C
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Measurements
HDL2-C increase
24.6%
goserelin
Source sentences
Summary
Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642503
06HumanNon-randomized trialActivity measurement
In endometriosis patients, goserelin significantly increased HDL3-C by 45.7%.
In plain wordsIn endometriosis patients, goserelin increased HDL3 cholesterol by 45.7%.
Peptide
Goserelin
Outcome
IncreaseHDL3-C
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Measurements
HDL3-C increase
45.7%
goserelin
Source sentences
Summary
Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642504
07HumanNon-randomized trialActivity measurement
In endometriosis patients, goserelin did not significantly change LDL-C.
In plain wordsIn endometriosis patients, goserelin did not significantly change LDL cholesterol.
Peptide
Goserelin
Outcome
No significant changeLDL-C
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642505
08HumanNon-randomized trialActivity measurement
In endometriosis patients, goserelin did not significantly change ApoA-1.
In plain wordsIn endometriosis patients, goserelin did not significantly change ApoA-1.
Peptide
Goserelin
Outcome
No significant changeApoA-1
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642506
09HumanNon-randomized trialActivity measurement
In endometriosis patients, goserelin did not significantly change ApoB.
In plain wordsIn endometriosis patients, goserelin did not significantly change ApoB.
Peptide
Goserelin
Outcome
No significant changeApoB
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Goserelin induced a significant elevation in HDL-C (by 31.4%), in HDL2-C (24.6%) and in HDL3-C (45.7%) but no significant change in LDL-C or in ApoA-1 and ApoB.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642507
10HumanNon-randomized trialActivity measurement
In endometriosis patients, HDL remained elevated two months after goserelin treatment.
In plain wordsIn endometriosis patients, HDL remained elevated two months after goserelin treatment.
Peptide
Goserelin
Outcome
IncreasePost-treatment HDL
Study
n = 20
Outcome group
Lipids · Metabolic and weight
Studied dose
3.6 mg/4 weeks · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
These changes reverted 2 months after danazol while HDL was still elevated after goserelin.
1 context sentence(design, population, supporting numbers)
Summary · context
A randomized study in 33 patients comparing goserelin (3.6 mg/4 weeks s.c., n = 20) with danazol (2 x 400 mg/day p.o., n = 13) in patients with a laparoscopic diagnosis of endometriosis and treated for 6 months.
Report a problemFND-0183642510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.